Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.

Zacks Investment Research • Sep 3, 2026

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Zacks Investment Research • Sep 3, 2026

3 Cheap International Stocks to Buy

These stocks have economic moats and look attractive today.

Morningstar • Aug 19, 2026

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

Zacks Investment Research • Aug 5, 2026

Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again

Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to ​focus on a fresh disappointment in U.S. patient volumes ‌and the management's decision to merely confirm, not raise, the full-year guidance.

Reuters • Aug 4, 2026

Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights

Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.

MarketBeat • Aug 4, 2026

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further

Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.

WSJ • Aug 4, 2026

Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook

Fresenius Medical Care on Monday reported second-quarter operating income well ahead of ​market expectations and reaffirmed its full-year outlook, ‌as its cost-cutting programme and favourable U.S. reimbursement rates offset a deepening decline in patient ​treatment volumes.

Reuters • Aug 3, 2026

Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.

Proactive Investors • Jul 23, 2026